MENU
ESPR
AS OF
Feb 4, 03:53 PM (EDT)
Price
$3.48
Change
-$0.03 (-0.85%)
Capitalization
839.11M
20 days until earnings call
Intraday BUY SELL Signals
+Compare
ESPR
Stock ticker: NASDAQ
AS OF
Feb 4, 03:53 PM (EDT)
Price
$3.48
Change
-$0.03 (-0.85%)
Capitalization
839.11M

ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis

Esperion Therapeutics Inc is a pharmaceutical company... Show more

Industry: #Biotechnology
ESPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ESPR with price predictions
Feb 03, 2026

Aroon Indicator for ESPR shows an upward move is likely

ESPR's Aroon Indicator triggered a bullish signal on January 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 170 similar instances where the Aroon Indicator showed a similar pattern. In of the 170 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ESPR's RSI Oscillator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 28, 2026. You may want to consider a long position or call options on ESPR as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESPR just turned positive on January 28, 2026. Looking at past instances where ESPR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

ESPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ESPR moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ESPR crossed bearishly below the 50-day moving average on January 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (29.792). P/E Ratio (0.000) is within average values for comparable stocks, (74.095). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.035). ESPR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (2.282) is also within normal values, averaging (116.680).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
ESPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ESPR is expected to report earnings to fall 282.25% to 29 cents per share on February 24

Esperion Therapeutics ESPR Stock Earnings Reports
Q4'25
Est.
$0.29
Q3'25
Missed
by $0.18
Q2'25
Beat
by $0.12
Q1'25
Missed
by $0.05
Q4'24
Beat
by $0.03
The last earnings report on November 06 showed earnings per share of -15 cents, missing the estimate of 1 cents. With 626.23K shares outstanding, the current market capitalization sits at 839.11M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3891 Ranchero Drive
Phone
+1 734 887-3903
Employees
240
Web
https://www.esperion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFILX16.540.14
+0.85%
Schwab Fundamental Intl Sm Eq Idx
DDVRX12.620.09
+0.72%
Nomura Value R
JABIX12.460.04
+0.32%
JHancock Real Estate Securities R6
ARAHX6.14N/A
N/A
Aristotle Small/Mid Cap Equity A
LGLRX49.95-0.67
-1.32%
Lord Abbett Growth Leaders R3

ESPR and Stocks

Correlation & Price change

A.I.dvisor tells us that ESPR and AQST have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and AQST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+0.29%
AQST - ESPR
29%
Poorly correlated
N/A
HROW - ESPR
27%
Poorly correlated
+5.10%
ALKS - ESPR
27%
Poorly correlated
-1.40%
ZOMDF - ESPR
26%
Poorly correlated
-6.22%
ANIP - ESPR
26%
Poorly correlated
-0.15%
More

Groups containing ESPR

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+0.29%
Pharmaceuticals: Generic
industry (214 stocks)
26%
Poorly correlated
-0.59%